Codon-Optimized RS1 Expression Vector for XLRS Protein Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for X-linked retinoschisis lack effective delivery vectors for the RS1 gene, hindering gene therapy progress.
Innovation Solution
Development of a codon-optimized RS1 gene expression vector, integrated with non-coding regulatory sequences and packaged in an AAV2/8 vector, to enhance mRNA and protein expression levels, administered via intraocular injection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery vectors are used to deliver the RS1 gene, then gene therapy can be attempted, but the expression level of RS1 protein is insufficient to achieve effective treatment
Solution Approach 1:
The patent applies codon optimization to the RS1 gene sequence, changing the nucleotide composition while maintaining the amino acid sequence. This parameter change at the molecular level enhances translation efficiency and protein expression levels. The optimized gene sequence is then packaged in AAV vectors to achieve high-level, sustained expression of RS1 protein in retinal cells, directly resolving the contradiction between achieving effective treatment and sufficient protein expression.
2Productivity
If the RS1 gene is delivered without codon optimization, then the treatment approach is simpler, but the mRNA and protein expression levels are only 5-7 times baseline, which is insufficient for effective therapy
Solution Approach 1:
The patent optimizes multiple parameters of the gene expression vector including codon usage frequency, GC content, mRNA stability elements, and promoter strength. These parameter changes collectively enhance transcription and translation efficiency, achieving 12-16 times baseline expression levels. The increased complexity in vector design is justified by the substantial improvement in therapeutic protein production.
Solution Approach 2:
The patent constructs a composite gene expression system combining the optimized RS1 gene sequence with AAV2/8 viral vector components, including specific promoter elements, polyadenylation signals, and regulatory sequences. This composite structure integrates multiple functional elements that work synergistically to achieve high-level, sustained gene expression, resolving the contradiction between expression productivity and design complexity.
3Manufacturing precision
If existing expression vectors are used, then the development process is faster, but the expression efficiency is insufficient with only 5-7 fold increase over baseline
Solution Approach 1:
The patent performs preliminary codon optimization and regulatory element selection during the vector construction phase, rather than attempting to improve expression later. The RS1 gene sequence is pre-optimized for human cellular translation machinery, and the AAV2/8 vector is pre-configured with optimal promoter and regulatory elements. This preliminary action ensures high expression efficiency from the first administration, avoiding the need for iterative screening and reducing overall development time.
Data Source
AI summary
Use of the RS1 gene in preparing a therapeutic agent for X-linked juvenile retinoschisis is provided. The RS1 gene in an RS1 gene expression cassette is subjected to codon optimization, and the nucleotide sequence of said gene is as shown in SEQ ID NO: 6. In an in-vitro expression experiment, the mRNA level of the RS1 gene expression cassette after codon optimization was about five times that of the original RS1 gene expression cassette, and the protein level was about seven times that of the original.